{"denoms":[{"counts":[{"groupId":"BG000","value":"158"},{"groupId":"BG001","value":"157"},{"groupId":"BG002","value":"315"}],"units":"Participants"}],"groups":[{"description":"Best Supportive Care: Corticosteroid (either prednisolone 30 mg orally (PO) every other day, dexamethasone 6 mg PO every other day, or other equivalent corticosteroid).\n\nOptional cyclophosphamide 50 mg PO once daily may be given at the Investigator's discretion (maximum of 1400 mg per 28-day cycle).","id":"BG000","title":"Best Supportive Care"},{"description":"Carfilzomib: 20mg/m² IV on Days 1 and 2 of Cycle 1, escalating to 27 mg/m² IV on Days 8,9,15,and 16 of Cycle 1 and continuing on Days 1,2,8,9,15,and 16 of Cycles 2 through Cycle 9. Cycles 10 and beyond will receive 27 mg/m² IV on Days 1,2,15, and 16 (alternatively, the investigator could choose to continue the dosing frequency on the original dosing days \\[Days 1, 2, 8, 9, 15, 16\\] for individual subjects).","id":"BG001","title":"Carfilzomib"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.02","value":"65.5"},{"groupId":"BG001","spread":"10.71","value":"63.3"},{"groupId":"BG002","spread":"9.50","value":"64.4"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"62"},{"groupId":"BG001","value":"75"},{"groupId":"BG002","value":"137"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"96"},{"groupId":"BG001","value":"82"},{"groupId":"BG002","value":"178"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}],"title":"American Indian or Alaska Native"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"5"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}],"title":"Native Hawaiian or Other Pacific Islander"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"148"},{"groupId":"BG001","value":"151"},{"groupId":"BG002","value":"299"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"9"}]}],"title":"Other"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"138"},{"groupId":"BG001","value":"140"},{"groupId":"BG002","value":"278"}]}],"title":"Europe"},{"categories":[{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"37"}]}],"title":"Non-Europe"}],"paramType":"NUMBER","title":"Region","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"36"}]}],"title":"3"},{"categories":[{"measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"69"}]}],"title":"4"},{"categories":[{"measurements":[{"groupId":"BG000","value":"104"},{"groupId":"BG001","value":"106"},{"groupId":"BG002","value":"210"}]}],"title":"≥5"}],"paramType":"NUMBER","title":"Number of Prior Regimens to Treat Multiple Myeloma","unitOfMeasure":"participants"}]}